gracecastuc-061_lung_dr. sandler: my approach to acquired resistance for targeted therapies in lc
Published 11 years ago • 38 plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
7:24
gracecastuc-025_lung_dr. riely on approach for acq. resistance to targeted therapies in adv. nsclc
-
1:45
gracecastuc-034_lung_management strategies for acquired resistance to targeted therapies
-
8:46
grace targeted therapies in lung cancer 2021 - liquid and tissue biopsies in acquired resistance
-
7:03
living with advanced cancer: handling uncertainty - targeted therapies in lung cancer 2023
-
4:07
gracecastuc-064_lung_drs. camidge and langer: how should we manage acquired resistance?
-
21:33
optimal ngs platforms, how to interpret - grace targeted therapies in lung cancer patient forum 2021
-
6:04
resistance on targeted therapy: questions patients should ask-targeted therapies in lung cancer 2023
-
3:02
the future of ret nsclc treatment - targeted therapies in lung cancer 2023
-
1:15
gracecastuc-054_lung_wakelee: my approach to repeat biopsies for adv. nsclc with insufficient tissue
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
17:40
liquid biopsies: current applications - grace targeted therapies in lung cancer patient forum 2021
-
0:13
the importance of biomarker testing- targeted therapies in lung cancer 2023- #shorts #youtubeshorts
-
2:56
barriers to drug development for kras g12c nsclc - targeted therapies in lung cancer 2023
-
3:50
grace targeted therapies in lung cancer 2021 - liquid biopsy - screening tool to detect lung cancer?
-
3:10
gracecastuc-062_lung_dr. spigel: we've probably made maint. therapy more complicated than necessary
-
0:31
biomarkers in nsclc - targeted therapies in lung cancer 2023 - #youtubeshorts #shorts
-
2:34
grace targeted therapies lung cancer 2021 - recommended firstline treatment for kras k12c?
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
24:30
gracecast-100_lung-cancer_mm in lc pt 5: dr. spigel on incorporating targets into clinical trials